TY - JOUR
T1 - Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases
AU - Akoumianakis, Ioannis
AU - Sanna, Fabio
AU - Margaritis, Marios
AU - Badi, Ileana
AU - Akawi, Nadia
AU - Herdman, Laura
AU - Coutinho, Patricia
AU - Fagan, Harry
AU - Antonopoulos, Alexios S.
AU - Oikonomou, Evangelos K.
AU - Thomas, Sheena
AU - Chiu, Amy P.
AU - Chuaiphichai, Surawee
AU - Kotanidis, Christos P.
AU - Christodoulides, Constantinos
AU - Petrou, Mario
AU - Krasopoulos, George
AU - Sayeed, Rana
AU - Lv, Lei
AU - Hale, Ashley
AU - Kararoudi, Meisam Naeimi
AU - McNeill, Eileen
AU - Douglas, Gillian
AU - George, Sarah
AU - Tousoulis, Dimitris
AU - Channon, Keith M.
AU - Antoniades, Charalambos
N1 - Publisher Copyright:
Copyright © 2019 The Authors.
PY - 2019/9/18
Y1 - 2019/9/18
N2 - Obesity is associated with changes in the secretome of adipose tissue (AT), which affects the vasculature through endocrine and paracrine mechanisms. Wingless-related integration site 5A (WNT5A) and secreted frizzled-related protein 5 (SFRP5), adipokines that regulate noncanonical Wnt signaling, are dysregulated in obesity. We hypothesized that WNT5A released from AT exerts endocrine and paracrine effects on the arterial wall through noncanonical RAC1-mediated Wnt signaling. In a cohort of 1004 humans with atherosclerosis, obesity was associated with increased WNT5A bioavailability in the circulation and the AT, higher expression of WNT5A receptors Frizzled 2 and Frizzled 5 in the human arterial wall and increased vascular oxidative stress due to activation of NADPH oxidases. Plasma concentration of WNT5A was elevated in patients with coronary artery disease compared to matched controls and was independently associated with calcified coronary plaque progression. We further demonstrated that WNT5A induces arterial oxidative stress and redox-sensitive migration of vascular smooth muscle cells via Frizzled 2-mediated activation of a previously uncharacterized pathway involving the deubiquitinating enzyme ubiquitin-specific protease 17 (USP17) and the GTPase RAC1. Our study identifies WNT5A and its downstream vascular signaling as a link between obesity and vascular disease pathogenesis, with translational implications in humans.
AB - Obesity is associated with changes in the secretome of adipose tissue (AT), which affects the vasculature through endocrine and paracrine mechanisms. Wingless-related integration site 5A (WNT5A) and secreted frizzled-related protein 5 (SFRP5), adipokines that regulate noncanonical Wnt signaling, are dysregulated in obesity. We hypothesized that WNT5A released from AT exerts endocrine and paracrine effects on the arterial wall through noncanonical RAC1-mediated Wnt signaling. In a cohort of 1004 humans with atherosclerosis, obesity was associated with increased WNT5A bioavailability in the circulation and the AT, higher expression of WNT5A receptors Frizzled 2 and Frizzled 5 in the human arterial wall and increased vascular oxidative stress due to activation of NADPH oxidases. Plasma concentration of WNT5A was elevated in patients with coronary artery disease compared to matched controls and was independently associated with calcified coronary plaque progression. We further demonstrated that WNT5A induces arterial oxidative stress and redox-sensitive migration of vascular smooth muscle cells via Frizzled 2-mediated activation of a previously uncharacterized pathway involving the deubiquitinating enzyme ubiquitin-specific protease 17 (USP17) and the GTPase RAC1. Our study identifies WNT5A and its downstream vascular signaling as a link between obesity and vascular disease pathogenesis, with translational implications in humans.
UR - http://www.scopus.com/inward/record.url?scp=85072386665&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072386665&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.aav5055
DO - 10.1126/scitranslmed.aav5055
M3 - Article
C2 - 31534019
AN - SCOPUS:85072386665
SN - 1946-6234
VL - 11
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 510
M1 - eaav5055
ER -